PBI22 Rethinking the Health-Economic Evaluation Framework for GENE Therapies: The Betibeglogene Autotemcel (BETI-CEL) Case in Î’-Thalassemia

Abstract

Authors

L. Undreiner M. Caillon C. Paramore S. Roze

Full Text Cite This Article
Back to Volume 23, Supplemental S2
Your browser is out-of-date

ISPOR recommends that you update your browser for more security, speed and the best experience on ispor.org. Update my browser now

×